ID: MRFR/HC/5928-CR | 141 Pages | Author: Rahul Gotadki | July 2023
The Plasma Fractionation Market size was valued at USD 29.86 billion in 2022 and is projected to grow from USD 32.21 Billion in 2023 to USD 71.3 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.1% during the forecast period (2023 - 2032). The growing use of immunoglobulins for various therapeutic areas and demand for plasma derived medicinal products drives the market growth are driving market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Immunoglobulins are used as first-line therapy for various neurologic, immunologic, and hematologic conditions. In the last decade, the diagnosis rate of various immunological diseases has increased due to technological advancements. The growing genetic research for characterizing and diagnosing immunodeficiency will also increase the clinical need for immunoglobulins due to the increased number of diagnosed patients. According to IG Living, a magazine for the immune globulin (IG) community, there are several on- and off-label indications of IV-Ig. In recent years, the use of off-label indications of immunoglobulin has exceeded that of on-label indications; off-label indications of immunoglobulin account for around 20—60% of its clinical use.
Furthermore, the prevalence of rare and autoimmune diseases and an increase in immunology research worldwide are further driving the growth of this segment. According to data published by the National Center for Advancing Translational Sciences in February 2022, there are approximately 7,000 to 10,000 rare diseases affecting humans, of which only a few hundred have any treatment. Further, the rising number of rare diseases is contributing to the growth of the immunoglobulin market segment.
This statistic shows the worldwide albumin consumption in metric tons from 2018 to 2019 and forecasts until 2026. In 2018, more than 920 metric tons of albumin were consumed worldwide. Moreover, Albumin is a globular protein generated from blood plasma. It is used mostly for cancer diagnostics and therapies, and Morbus Wilson treatments.
Figure 1: Worldwide albumin consumption from 2018 to 2026
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
The Market segments of Plasma Fractionation, based on product type, includes immunoglobulin, coagulation factor concentrates, albumin, protease inhibitors, and others. The immunoglobulin segment held the majority share in 2022 in the Plasma Fractionation Market revenue. This is due to the increasing prevalence of immunodeficiency diseases, the rising geriatric population, and advancements in plasma collection and fractionation technologies. Moreover, Immunoglobulin is becoming more extensively used for the administration, cure, and identification of metabolic disorders globally, which is one of the most significant aspects influencing the industry's expansion. As a result, immunoglobulin's extensive use will also increase its supremacy and enhance market opportunities.
January 2022: Permira announced a partnership with the Marucci family and FSI, the existing shareholders of Kedrion S.p.A., to jointly acquire and combine Kedrion and Bio Products Laboratory (BPL). The two companies' partnership would create a global player for medicines derived from human plasma to treat life-threatening and rare conditions
The Plasma Fractionation Market segmentation is based on Application that includes, immunology, neurology, hematology, critical care, pulmonology, rheumatology, hemato-oncology, and others. The neurology segment has dominated the market in 2022 and immunology segment is projected to be the fastest-growing segment during the forecast period, 2023-2032. This is attributed to the increased application off immunoglobulin for chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), myasthenia gravis, and inflammatory myopathies, shorter period response period of IVIG than steroids or oral immunosuppressants, rise in a number of patients suffering from neurological disease, and increase research and development for use of IVIg for other indications related to neurology, including Alzheimer's disease.
Figure 2: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
The Market segmentation of Plasma Fractionation is based on an end-user that includes hospitals & clinics, clinical research laboratories, academic institutes, and others. The hospitals & clinics segment has dominated the market in 2022 and is projected to be the fastest-growing segment during the forecast period, 2023-2032. This is due to the increasing number of people opting for plasma-derived therapies across the globe. Moreover, various private hospitals with improved infrastructure and technology have adopted plasma-derived therapies and are prescribing their patients suffering from rare immunodeficiency diseases. For example, the Brazilian Rare Disease Network (BRDN) is under development, comprising 40 institutions, including 18 university hospitals, 17 Rare Diseases Reference Services, and five Newborn Screening Reference Services. Thus, with increased off-label use of plasma fractionation products in hospitals to treat a variety of diseases, improved infrastructure & healthcare services offered by hospitals, the segment is anticipated to witness significant growth.
April 2020: Grifols launched a 3- ml vial for Hyper RAB which is rabies immune globulin in the plasma fractionation market to help in the treatment of rabies cases across the world.
By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North American plasma fractionation market accounted for the largest market share in 2022. This is due to the rising prevalence of various genetic diseases, the growing geriatric population, and increasing healthcare expenditure in the region. For instance, according to the March 2021 report of the Alzheimer's Association, approximately 6.2 million people of age 65 years and more are living with Alzheimer's-related dementia in the US. It is projected that this number will increase to 13.8 people by 2060. Thus, the high prevalence of Alzheimer's disease and the effectiveness of the plasma fractionation product in the treatment bolster the market growth over the forecast period.
Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: PLASMA FRACTIONATION MARKET SHARE BY REGION 2022 & 2032
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe plasma fractionation market accounts for the second-largest market share due to the rising prevalence of immunodeficiency and bleeding disorders in the region and increasing investments in these systems. further, the Germany market of plasma fractionation was attributed to hold the largest market share, and the UK market of plasma fractionation is expected to fastest-growing market in the European region.
The Asia-Pacific plasma fractionation market is expected to grow at a significant share from 2023 to 2032. This is due to an increase in public and private funding for research and development, favorable government regulations, increased use of immunoglobulins, rising prevalence of target diseases with an aging population with blood-related diseases, and rising plasma-based treatment adoption in the Asia-Pacific region. Moreover, China market of plasma fractionation is expected to hold the largest market share, and India market of plasma fractionation is expected fastest-growing market in the Asia-Pacific region.
Furthermore, the growing prevalence of hemophilia in Asian countries is expected to positively affect the market growth in Asia Pacific. For instance, according to a study published by the Annals of Blood in 2018, the factor VIII IU’s per capita consumption in Japan and China is 4.0 and 0.1, respectively. Furthermore, an increase in the geriatric population, a rise in government support through Medicaid and healthcare policies, and developments in the healthcare infrastructure are other factors that are likely to have considerable market growth for the plasma fractionation.
The Rest of the World is segmented into the Middle East, Africa, and Latin America. plasma fractionation market in the above-mentioned regions is likely to witness growth due to the prevalence of autoimmune diseases in the regions. Moreover, The United Arab Emirates (UAE), Saudi Arabia and South Africa are the 3 major countries in the MEA. Saudi Arabia was the largest market for Plasma fractionation in this region in 2022. Furthermore, the market for plasma fractionation in the MEA is anticipated to grow due to the rising prevalence of various diseases and increasing government initiatives in the region.
Plasma Fractionation Key Market Players & Competitive Insights
The Plasma Fractionation Market is characterized by the presence of many global, regional, and local vendors catering to the demand created by research scientists and pharmaceutical and biotechnology companies operating in the industry. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reach across the globe with diverse product portfolios. Companies such as CSL Behring (US), Grifols Therapeutics (Spain), Baxter International Inc (US), and Mitsubishi Tanabe (Japan) dominate the Plasma Fractionation Market due to product differentiation, financial stability, strategic developments, and diversified regional presence. The players are focused on investing in research and development. Furthermore, they adopt strategic growth initiatives, such as expansion, product launches, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.
One of the primary business strategies adopted by manufacturers in the global plasma fractionation industry to benefit clients and expand the plasma fractionation market sector is to manufacture locally to reduce operating costs.
CSL Behring is a biopharmaceutical company, manufacturing plasma-derived, and recombination therapeutic products. Its line of therapies includes products for the treatment of bleeding disorders such as hemophilia; hereditary angioedema; inherited respiratory disease; and neurological disorders. CSL Behring is focused on serving patients with serious and rare diseases, including coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease and neurological disorders. Furthermore, the parent company, CSL Limited, headquartered in Melbourne, Australia, employs more than 27,000 people, and provides its life-saving medicines in more than 70 countries. CSL Limited is the parent company of global biotechnology leader CSL Behring; the world's largest collector of human plasma, CSL Plasma; and global leader in influenza prevention, Seqirus. CSL Limited is based in Melbourne, Victoria, Australia, and is traded on the Australian Securities Exchange (ASX) under the symbol CSL. For instance, in December 2022, CSL Behring (US) unveiled the future of plasma manufacturing in Australia with the opening of their USD 900 million Plasma Fractionation Facility in Victoria, the largest of its kind in the Southern Hemisphere. This is part of a USD 2 billion-plus capital investment program CSL currently has underway in Australia.
Key Companies in the market of Plasma Fractionation include
Plasma Fractionation Industry Developments
January 2022: Bio Products Laboratory Ltd. announced that the National Medical Products Administration (NMPA) for China granted the company a license to market ALBUMINEX 25% in China.
June 2021: LFB Plasma announced the acquisition of ImmunoTek Bio Center. The acquisition of the plasma collection center will ensure a steady and reliable supply of plasma in the U.S.
April 2021: CSL Plasma and Terumo Blood and Cell Technologies announced a collaboration to develop and deliver a new plasma collection platform at the U.S. CSL Plasma Collection Centers.
January 2022: - Kedrion S.p.A (Italy) and LFB formed an industrial cooperation agreement to increase the availability of immunoglobulins for patients in France. Following the agreement, immunoglobulins manufactured by Kedrion S.p.A will be imported by LFB in France and distributed among hospitals in this region along with their own immunoglobulins.
Report Attribute/Metric | Details |
Market Size 2022 | USD 29.86 billion |
Market Size 2023 | USD 32.21 billion |
Market Size 2032 | USD 71.3 billion |
Compound Annual Growth Rate (CAGR) | 9.1% (2023-2032) |
Base Year | 2022 |
Forecast Period | 2023-2032 |
Historical Data | 2019 & 2021 |
Forecast Units | Value (USD Billion) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Product Type, Application, end user, and Region |
Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
Countries Covered | The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea. |
Key Companies Profiled | CSL Behring (US), Grifols Therapeutics (Spain), Baxter International Inc (US), Mitsubishi Tanabe (Japan), Takeda Pharmaceutical (Japan), Octapharma AG (Switzerland), Hualan Bio (China), Kedrion S.p.A (Italy), LFB group (France), and Biotest AG (Germany) |
Key Market Opportunities | Launch of new technologies by key players to augment market growth |
Key Market Dynamics | Growing use of immunoglobulins for various therapeutic areaDemand for Plasma Derived Medicinal Products |
The Plasma Fractionation Market is anticipated to reach 71.3 billion at a CAGR of 9.1% during the forecast period of 2023-2032.
The US is expected to hold over 75% share of the North America market for plasma fractionation market during the forecast period of 2023-2032.
The plasma fractionation market is expected to grow at an 9.1% CAGR during the forecast period from 2023 to 2032.
The North American region market held the largest market share in the plasma fractionation market.
The key players include CSL Behring (US), Grifols Therapeutics (Spain), Baxter International Inc (US), Mitsubishi Tanabe (Japan), Takeda Pharmaceutical (Japan), Octapharma AG (Switzerland), Hualan Bio (China), Kedrion S.p.A (Italy), LFB group (France), and Biotest AG (Germany).
The neurology segment was estimated to lead the plasma fractionation market.
The hospitals & clinics segment is attributed to having the largest market share based on end user.
Key Questions Answered
Why Choose Market Research Future?